The global Biologics Industry was valued at US$ 515.6 billion in 2022 and is projected to grow at a CAGR of 6.9% from 2023 to ...
Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa contin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback